News & Updates

Cefepime-taniborbactam trumps meropenem for complicated UTI
Cefepime-taniborbactam trumps meropenem for complicated UTI
26 Oct 2022 byTristan Manalac

Cefepime-taniborbactam (FTB) is significantly better than meropenem for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis (AP), according to results of the Cefepime Rescue with Taniborbactam in cUTI (CERTAIN-1) study presented at the recent ID Week 2022.

Cefepime-taniborbactam trumps meropenem for complicated UTI
26 Oct 2022
Hepatitis B vaccine with TLR-9 agonist achieves high protection in people with HIV
Hepatitis B vaccine with TLR-9 agonist achieves high protection in people with HIV
25 Oct 2022 byTristan Manalac

Among people living with HIV (PLHIV), immunization with a hepatitis B surface antigen (HBsAg)-based vaccine adjuvanted with a toll-like receptor (TLR)-9 agonist can induce a 100-percent seroprotection rate, according to a study presented at the recently concluded Virtual ID Week 2022.

Hepatitis B vaccine with TLR-9 agonist achieves high protection in people with HIV
25 Oct 2022
Prophylactic anticoagulation in critical COVID-19: Is full-dose or standard-dose preferred?
Prophylactic anticoagulation in critical COVID-19: Is full-dose or standard-dose preferred?
23 Oct 2022
Topical antibiotics work well against acute infectious conjunctivitis in children
Topical antibiotics work well against acute infectious conjunctivitis in children
17 Oct 2022
Pre-DAA IL-1β can predict HBV reactivation in HCV
Pre-DAA IL-1β can predict HBV reactivation in HCV
14 Oct 2022

Among hepatitis C virus (HCV) patients with resolved hepatitis B virus (HBV) infections, levels of interleukin (IL)-1β before the initiation of direct-acting antiviral (DAA) treatment may help predict HBV reactivation, reports a recent study.

Pre-DAA IL-1β can predict HBV reactivation in HCV
14 Oct 2022